Personalized Medicine

Recent Developments in Genomic-Driven Therapies for Cholangiocarcinoma

Cholangiocarcinoma, Personalized Medicine

June/July 2021, Vol 2, No 2 — July 28, 2021

Personalized medicine has expanded the treatment options for patients with cholangiocarcinoma (CCA). At the 2021 Annual Meeting of the Cholangiocarcinoma Foundation (CCF), Ghassan K. Abou-Alfa, MD, MBA, Professor of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, discussed recent developments in personalized therapies, highlighting genomic alterations that are informing the new therapies for patients with CCA.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

CCA News Print Edition

CCA News Weekly e‑Newsletter

Personalized Medicine

Subscribe Today!

I'd like to receive:

Stay In The Know